Tuberous sclerosis complex–associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Tuberous sclerosis complex (TSC) is a dominantly inherited disease caused by hyperactivation of the mTORC1 pathway and characterized by the development of hamartomas and benign tumors, including in the brain. Among the neurological manifestations associated with TSC, the tumor progression of static subependymal nodules (SENs) into subependymal giant cell astrocytomas (SEGAs) is one of the major causes of morbidity and shortened life expectancy. To date, mouse modeling has failed in reproducing these 2 lesions. Here we report that simultaneous hyperactivation of mTORC1 and Akt pathways by codeletion of Tsc1 and Pten, selectively in postnatal neural stem cells (pNSCs), is required for the formation of bona fide SENs and SEGAs. Notably, both lesions closely recapitulate the pathognomonic morphological and molecular features of the corresponding human abnormalities. The establishment of long-term expanding pNSC lines from mouse SENs and SEGAs made possible the identification of mTORC2 as one of the mediators conferring tumorigenic potential to SEGA pNSCs. Notably, in spite of concurrent Akt hyperactivation in mouse brain lesions, single mTOR inhibition by rapamycin was sufficient to strongly impair mouse SEGA growth. This study provides evidence that, concomitant with mTORC1 hyperactivation, sustained activation of Akt and mTORC2 in pNSCs is a mandatory step for the induction of SENs and SEGAs, and, at the same time, makes available an unprecedented NSC-based in vivo/in vitro model to be exploited for identifying actionable targets in TSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, the pharmacokinetics of NV-5138 in rodents is relatively short (~3 hours) and the extent of mTORC1 activation is limited (2- to 3-fold) compared with genetically induced hyperactivation (6- to 8-fold) that has been associated with pathological etiologies of mTORC1 hyperaction (e.g., development of TSC (47).”
From Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation (2019) · cites this paper as [47]
In the citing paper
“While it is true that the chronic hyperactivation of mTORC1 induced either genetically or through natural mutations (e.g., TSC1/2 inactivation) has been associated with the development and/or propagation of certain cancers, this is quite different from the observed effects of NV-5138 on mTORC1 activation in the current context.”
From Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation (2019) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 4×
“Acknowledgments We thank Giulia Scotti and Ivan Molineris at the Centre for Translational Genomics and Bioinformatics, Ospedale San Raffaele, for RNA-Seq data processing, GSEA, and meta-analysis.”
MethodInfluentialProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“Thus, the superior efficacy of rapamycin treatment on the growth of mouse SEGAs in comparison with the dual PI3K-mTOR kinase inhibitor PI-103 as described in our study might relate to the observation that prolonged rapamycin treatment strongly impairs Akt signaling by very efficiently interfering with the assembly of…”
BackgroundCuratolo, P., Bombardieri, R., & Jozwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,088
Gritti, A., Parati, E., Cova, L., Frolichsthal, P., Galli, R., Wanke, E., Faravelli, L., Morassutti, D., Roisen, F., Nickel, D., et al. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01091.1996 · Cited by 1,030
Self-citationNeural stem cells and neurospheres—re-evaluating the relationship
Reynolds, B. A., & Rietze, R. L. (2005) · Nature Methods · doi:10.1038/nmeth758 · Cited by 673 · cited 3×
“Isolation and characterization of pNSCs from control and mutant TPN mice. pNSC cultures were established by neurosphere assay (NSA) (38) under mildly hypoxic (5% O2) culture conditions from the SVZ of adult control and mutant P10 and P15–17 TPN mice.”
BackgroundInfluentialA Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“Given that we did not find any mutation in PTEN or in proteins interacting with it in human SENs/SEGA, other genetic events might be responsible for the negative-feedback loop inactivity and/ or for the increase in Akt signaling in human lesions, such as those recently described that lead to activation of the PI3K/AKT…”
BackgroundA dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585 · cited 1×
“into nude mice, and, when tumor volume reached 10–20 mm3 42 days after transplant, animals were randomized and treated for 5 days a week with either rapamycin (6 mg/kg) or the dual PI3K-mTOR inhibitor PI-103 (5 mg/kg) (22) up to 4 weeks.”
MethodThe Adult Ventricular–Subventricular Zone (V-SVZ) and Olfactory Bulb (OB) Neurogenesis
Lim, D. A., & Alvarez-Buylla, A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018820 · Cited by 571 · cited 1×
“Patients’ SENs and SEGAs arise in the SVZ, which surrounds the lateral ventricles and comprises NSCs that persist postnatally (16).”
BackgroundThe TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511 · cited 1×
“Loss of the Tsc1-Tsc2 complex is known to attenuate mTORC2 activation, independent of Rheb and of the mTORC1-dependent negative feedback on Akt (27).”
BackgroundInduction of Expansion and Folding in Human Cerebral Organoids
Li, Y., Muffat, J., Omer, A., Bosch, I., Lancaster, M. A., Sur, M., Gehrke, L., Knoblich, J. A., & Jaenisch, R. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.11.017 · Cited by 436 · cited 1×
“Accordingly, AKT hyperactivation through PTEN loss has been recently shown to promote cell cycle reentry and to delay neuronal differentiation in human neural progenitors (23).”
Background
Cited by
Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming
Bénéchet, A. P., De Simone, G., Di Lucia, P., Cilenti, F., Barbiera, G., Le Bert, N., Fumagalli, V., Lusito, E., Moalli, F., Bianchessi, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1620-6 · Cited by 222
Self-citationRole of mTOR Complexes in Neurogenesis
LiCausi, F., & Hartman, N. W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051544 · Cited by 165
De Simone, G., Andreata, F., Bleriot, C., Fumagalli, V., Laura, C., Garcia-Manteiga, J. M., Di Lucia, P., Gilotto, S., Ficht, X., De Ponti, F. F., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.005 · Cited by 154
Self-citationSestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126859 · Cited by 88
The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
Feliciano, D. M. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00039 · Cited by 69
“Moreover, this same group did not find evidence that PTEN is mutated in SEGAs (Zordan et al., 2018).”
BackgroundInfluentialAn update on the central nervous system manifestations of tuberous sclerosis complex
Cotter, J. A. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02003-1 · Cited by 54
Fu, X., Li, P., Zhang, L., Song, Y., An, Y., Zhang, A., Liu, W., Ye, C., Zhang, Y., Yue, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107357119 · Cited by 46
Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 44
“The manifestations in the CNS consist in subpendymal nodules (SENs) and SEGAs.”
BackgroundInfluentialmTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
Polchi, A., Magini, A., Meo, D. D., Tancini, B., & Emiliani, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051474 · Cited by 31
“Consistent with this, by inducible conditional transgenesis authors have demonstrated that codeletion of Tsc1 and Pten in postnatal neural stem cells is necessary for the development of SENs and SEGAs closely resembling human TSC lesions highlighting the relevance of both Akt and mTORC2 pathways for the induction of t…”
BackgroundAutophagic lipid metabolism sustains mTORC1 activity in TSC-deficient neural stem cells
Wang, C., Haas, M. A., Yang, F., Yeo, S. K., Okamoto, T., Chen, S., Wen, J., Sarma, P., Plas, D. R., & Guan, J. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0137-5 · Cited by 30
Location-dependent maintenance of intrinsic susceptibility to mTORC1-driven tumorigenesis
Rushing, G. V., Brockman, A. A., Bollig, M. K., Leelatian, N., Mobley, B. C., Irish, J. M., Ess, K. C., Fu, C., & Ihrie, R. A. (2019) · Life Science Alliance · doi:10.26508/lsa.201800218 · Cited by 18
“An additional mouse model co-deleted Tsc1 and Pten in postnatal NSCs and found tumors that closely recapitulated human tumors via hematoxylin and eosin staining (Zordan et al, 2018); however, to date, no TSC patients have been reported to have a mutation in Pten (Martin et al, 2017).”
BackgroundUnraveling the function of TSC1-TSC2 complex: implications for stem cell fate
Wang, S., Ma, R., Gao, C., Tian, Y.-N., Hu, R., Zhang, H., Li, L., & Li, Y. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04170-3 · Cited by 18
Kim, Y., Lee, J. S., & Joo, Y. H. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0838-2 · Cited by 14
Tsc2 coordinates neuroprogenitor differentiation
Riley, V. A., Shankar, V., Holmberg, J. C., Sokolov, A. M., Neckles, V. N., Williams, K., Lyman, R. A., Mackay, T. F. C., & Feliciano, D. M. (2023) · iScience · doi:10.1016/j.isci.2023.108442 · Cited by 10
Meulemeester, A.-S. D., Heylen, L., Siekierska, A., Mills, J. D., Romagnolo, A., van der Wel, N. N., Aronica, E., & de Witte, P. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.952832 · Cited by 6
“Accordingly, in other TSC-deficient models, giant cells and SEGA lesions were observed only after significant development time (Goto et al., 2011; Zordan et al., 2018; Nguyen et al., 2019).”
BackgroundModeling tuberous sclerosis with organoids
Ihrie, R. A., & Henske, E. P. (2022) · Science · doi:10.1126/science.abn6158 · Cited by 9
Bagh, M. B., Appu, A. P., Sadhukhan, T., Mondal, A., Plavelil, N., Raghavankutty, M., Supran, A. M., Sadhukhan, S., Liu, A., & Mukherjee, A. B. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105641 · Cited by 7
“Moreover, the loss of function mutations of TSC1 , TSC2 , PTEN , and STRAD α genes mediate mTORC1 activation, which causes epilepsy and neurobehavioral problems (80, 81).”
BackgroundA bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model
Mukherjee, S., Wolan, M. J., Scott, M. K., Riley, V. A., Sokolov, A. M., & Feliciano, D. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-08345-z · Cited by 7
“SENs and SEGAs share all histopathological features 16 .”
TSC-mTORC1 Pathway in Postnatal V-SVZ Neurodevelopment
Feliciano, D. M., & Bordey, A. (2025) · Biomolecules · doi:10.3390/biom15040573 · Cited by 5
Fukui, M., Katayama, S., Ikeya, Y., & Inazu, T. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02662 · Cited by 4
Tang, X., Angst, G., Haas, M., Yang, F., & Wang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084116 · Cited by 4
“Other mouse models have required additional genetic events, such as loss of PTEN, which does not occur in TSC patients [6].”
BackgroundIsolation and Culture of Neural Stem/Progenitor Cells from the Postnatal Periventricular Region
Ricca, A., Cascino, F., & Gritti, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1783-0_2 · Cited by 4
Self-citationSingle nuclei transcriptomics reveals cellular diversity in TSC subependymal giant cell astrocytomas
Holmberg, J. C., Shankar, V., Lyman, R. A., Mackay, T. F. C., & Feliciano, D. M. (2025) · iScience · doi:10.1016/j.isci.2025.113389 · Cited by 3
“…of a neuronal appearance within SEGA-like lesions near the ventricle marked by the neural stem cell marker nestin ( Figure 8F, G ) 25 . o o These data demonstrate some similarities between human SEGAs and mouse SEGA-like lesions, including the presence of cells that appear to be GABAergic neurons.”
Genomic sequencing in severe epilepsy: a step closer to precision medicine
Esposito, M., Lagorio, I., Peroni, D. G., Bonuccelli, A., Orsini, A. A., & Striano, P. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1732203 · Cited by 2
“The rationale of the use is that Sirolimus blocks mTOR complex which, if overexpressed, causes the formation of tumors, glial banda, and subependymal nodules both during fetal and postnatal central nervous system development [46].”
BackgroundYin, H.-Q., Li, X., Fu, Y. S., Zhu, H., & Luo, Y.-S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425988 · Cited by 1
Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line
Pagani, F., Gryzik, M., Somenza, E., Cominelli, M., Balzarini, P., Schreiber, A., Mattavelli, D., Nicolai, P., Doglietto, F., & Poliani, P. L. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030425 · Cited by 1
“We have previously reported that in an experimental model of TSC, concurrent hyperactivation of mTORC1 and Akt pathways mediated by co-deletion of TSC1 and PTEN is required for the formation of subependymal cell astrocytoma, a TSC-associated tumour [26].”
BackgroundSelf-citationLoss of Tsc2 in Neonatal V-SVZ Neural Stem Cells Causes Rare Malformations
Holmberg, J. C., Riley, V. A., Sokolov, A. M., Fisher, L. J., & Feliciano, D. M. (2026) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases4010006 · Cited by 1
“Nevertheless, SENs and SEGAs share histopathological features, and therefore it is reasonable to consider SENs as precursors to SEGAs [20].”
Control of ependymal cell differentiation by the mTOR signaling pathway
Srivastava, A. (2021) · theses.fr (ABES) · doi:10.70675/0e4dc286zfb40z4d2bza4cdzd6fdff1cc2e8
Metadata
- Authors
- Zordan, P., Cominelli, M., Cascino, F., Tratta, E., Poliani, P. L., & Galli, R.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- University of Brescia (IT)
- Corresponding author
- Galli, Rossella
- Venue
- Journal of Clinical Investigation
- Published
- 2018-03-12
- Volume
- 128
- Issue
- 4
- Pages
- 1688-1706
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5873854
- OpenAlex
- W2787744028
- Cited by
- 28
- References
- 40
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 3
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon (GGP13022)
- Associazione Sclerosi Tuberosa Italia (n/a)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- tuberous sclerosis complex, mTORC1, Akt, mTORC2, subependymal giant cell astrocytoma, subependymal nodules, neural stem cells, TSC1, PTEN, rapamycin, tumor progression, hamartoma, mouse model
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Astrocytoma, Brain Neoplasms, Mice, Transgenic, Tuberous Sclerosis, Proto-Oncogene Proteins c-akt, Mice, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.